The World Health Organization (WHO) announced on Friday that two monoclonal antibody treatments against Ebola The use of such drugs, combined with better care, has "revolutionized" the treatment of diseases once considered the probable cause of death.
drugs – Regeneron's Inmazeb (REGN-EB3) and Ridgeback Bio's Ebanga (mAb114) – use lab-made monoclonal antibodies that mimic natural antibodies in fighting off infections To do.
“Advancements in supportive care and treatment over the past decade have revolutionized Ebola care. Ebola virus disease was once recognized as a probable killer. No," said Robert Fowler, a professor at the University of Toronto, Canada and co-chair of the WHO's guideline development group. Effective care and the use of these treatments are now leading to the recovery of the "majority" of people from Ebola, he said, though he did not provide specific data. } 
The new recommendations follow 2018-2020 drug trials for hemorrhagic fevers in the Democratic Republic of the Congo. There. Dr Janet Diaz, head of clinical management for the WHO's health emergencies programme, told journalists that while drugs are now available in Congo, more work is needed to improve affordability.
